MARINUS PHARMACEUTICALS (MRNS) saw its loss widen to $28.64 million, or $1.47 a share for the year ended Dec. 31, 2016. In the previous year period, the company reported a loss of $24.85 million, or $1.67 a share.
The company has not recorded any revenues for the current as well as previous year.
Operating loss for the year was $28.24 million, compared with an operating loss of $24.43 million in the previous year.
"We enter 2017 focused on delivering clinical data to support advancing multiple formulations of ganaxolone in indications with few or no approved treatment options," said Christopher M. Cashman, chief executive officer of Marinus Pharmaceuticals. "We are in the process of initiating our Phase 2 clinical trial in women who suffer from postpartum depression, a mood disorder that occurs within weeks of childbirth. For status epilepticus, we have received regulatory feedback from FDA on the study protocol and are making preparations to initiate our Phase 2 clinical trial. With several near-term milestones on the horizon, 2017 has the potential to be a significant year for Marinus."
Debt comes down significantlyMARINUS PHARMACEUTICALS has recorded a decline in total debt over the last one year. It stood at $1.74 million as on Dec. 31, 2016, down 66.71 percent or $3.49 million from $5.24 million on Dec. 31, 2015. Total debt was 5.54 percent of total assets as on Dec. 31, 2016, compared with 8.78 percent on Dec. 31, 2015. Debt to equity ratio was at 0.08 as on Dec. 31, 2016, down from 0.11 as on Dec. 31, 2015. Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
